Moreover, FGL-1 expression within the tumor appeared to be correlated with the progression and prognosis of HCC, suggesting that FGL-1 could be used not only as a molecular target but also as a potential prognostic biomarker.67 More research is needed in order to understand if LAG-3 through FGL-1 blockade could have a role as a new therapeutic strategy to overcome resistance to immunotherapy. Here, FGL1 is linked to hepatocellular carcinoma.